Hepatitis A, B, C, D, E, G: An update

Ethnicity and Disease

Volumn 17, Issue 2, 2007, Pages

  Hall, Gairy F ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E; Hepatitis G; Interferon; Ribavirin

Indexed keywords

ADEFOVIR; DIPHENHYDRAMINE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS E VACCINE; HEPATITIS VACCINE; IMMUNOGLOBULIN; INTERFERON; LAMIVUDINE; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT VACCINE; RIBAMIDINE; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SILYBUM MARIANUM EXTRACT; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; THYROID HORMONE; UNCLASSIFIED DRUG; VX 950;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; AUTOIMMUNE DISEASE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DELTA AGENT HEPATITIS; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG COST; DRUG RESPONSE; DYSPNEA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS G; HEPATITIS G VIRUS; HEPATOMEGALY; HUMAN; INFECTION PREVENTION; INSOMNIA; IRRITABILITY; JAUNDICE; LEUKOPENIA; LIVER FUNCTION TEST; MENTAL DISEASE; MONEY; NAUSEA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY PREVENTION; PRURITUS; RASH; REMISSION; RETINOPATHY; SIDE EFFECT; SYMPTOM; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; URIC ACID BLOOD LEVEL; VOMITING;

GB VIRUS C; HEPACIVIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E VIRUS; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERONS; RIBAVIRIN; UNITED STATES;

EID: 34447542805     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. AGA guidelines: evaluation of LFTs. Gastroenterology. 2002;123:1364.
2. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266.
3. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science. 1973;182:1026.
4. Wheeler C, Vogt TM, Armstrong GL, et al. An outbreak of hepatitis A associated with green onions. N Engl J Med. 2005;353: 890-897.
5. Lee W. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
6. Gerberding JL. The infected health care provider. N Engl J Med. 1996;334:594.
7. Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
8. Yim HJ, Lok A. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173-S181.
9. Fong TL, DiBisceglie AM, Gerber MA, et al. Persistence of hepatitis B virus DNA in the liver after loss of HbsAg in chronic hepatitis B. Hepatology. 1993;18:1313-1318.
10. Komori M, Yuki N, Nagaoka T, et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatology. 2001;35:798-804.
11. Perrillo R, Gish R, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol. 2006;4:233-248.
12. Schiff ER. Treatment algorithm for hepatitis B and C. Gut. 1993;34(Suppl 2):S148-S149.
13. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993;119:312-323.
14. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the 2 in combination in patients with HBe antigen-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.
15. Keeffe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106.
16. Armstrong GL, Wasley A, Simard EP. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
17. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
18. NIH Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology. 1997;26:2S-10S.
19. Seef LB, Hoofnagle JH. NIH Consensus Development Conference: management of hepatitis C. Hepatology, 2002;(Suppl 1):S1.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358: 958-965.
21. Fried MW, Schiffman ML, Reddy K, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase II, randomized, activity-controlled, multicenter study. Gastroenterology. 2001;120:A-55 (abstract).
22. Davis GL, Wong JB, McHutchinson JG, Manns MP. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645.
23. Bonino F, Heermann KH, Rizzetto M, et al. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol. 1986;58:945.
24. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med. 2001;345(10):707-714.
25. Tillmann HL, Heiken H, Knapik-Botai A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001;345(10):715-724.